OBJECTIVE: To examine the safety and efficacy of fluoxetine in child and adolescent obsessive-compulsive disorder (OCD). METHOD:Between 1991 and 1998, 43 patients were randomly assigned to fluoxetine or placebo for 8 weeks. Dosing was fixed for the first 6 weeks (up to 60 mg/day) and then could be increased to 80 mg/day. Responders entered an 8-week maintenance phase. The primary outcome measures were the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinical Global Impression-Improvement (CGI-I) scale. Analyses were done on the intent-to-treat sample. RESULTS:Fluoxetinepatients (n = 21) had significantly lower CY-BOCS scores than placebopatients (n = 22) after 16 (but not 8) weeks. Fluoxetine responders (n = 11) had significantly lower CY-BOCS scores than placebo responders (n = 7) after an additional 8 weeks of treatment. After 16 weeks, 57% of fluoxetine (versus 27% of placebo) patients were much or very much improved on the CGI-I scale (p <.05). No patient terminated the study because of adverse medication effects. CONCLUSION:Fluoxetine was well tolerated and effective for the treatment of child and adolescent OCD, but fluoxetine's full effect took more than 8 weeks to develop.
RCT Entities:
OBJECTIVE: To examine the safety and efficacy of fluoxetine in child and adolescent obsessive-compulsive disorder (OCD). METHOD: Between 1991 and 1998, 43 patients were randomly assigned to fluoxetine or placebo for 8 weeks. Dosing was fixed for the first 6 weeks (up to 60 mg/day) and then could be increased to 80 mg/day. Responders entered an 8-week maintenance phase. The primary outcome measures were the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinical Global Impression-Improvement (CGI-I) scale. Analyses were done on the intent-to-treat sample. RESULTS:Fluoxetinepatients (n = 21) had significantly lower CY-BOCS scores than placebo patients (n = 22) after 16 (but not 8) weeks. Fluoxetine responders (n = 11) had significantly lower CY-BOCS scores than placebo responders (n = 7) after an additional 8 weeks of treatment. After 16 weeks, 57% of fluoxetine (versus 27% of placebo) patients were much or very much improved on the CGI-I scale (p <.05). No patient terminated the study because of adverse medication effects. CONCLUSION:Fluoxetine was well tolerated and effective for the treatment of child and adolescent OCD, but fluoxetine's full effect took more than 8 weeks to develop.
Authors: Joseph F McGuire; Nicole E Caporino; Sophie A Palitz; Philip C Kendall; Anne Marie Albano; Golda S Ginsburg; Boris Birmaher; John T Walkup; John Piacentini Journal: Depress Anxiety Date: 2019-06-24 Impact factor: 6.505
Authors: Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: Joseph F McGuire; John Piacentini; Adam B Lewin; Erin A Brennan; Tanya K Murphy; Eric A Storch Journal: Depress Anxiety Date: 2015-06-30 Impact factor: 6.505
Authors: J Freeman; J Sapyta; A Garcia; D Fitzgerald; M Khanna; M Choate-Summers; P Moore; A Chrisman; N Haff; A Naeem; J March; M Franklin Journal: Child Psychiatry Hum Dev Date: 2011-08
Authors: Paul J Grant; Lisa A Joseph; Cristan A Farmer; David A Luckenbaugh; Lorraine C Lougee; Carlos A Zarate; Susan E Swedo Journal: Neuropsychopharmacology Date: 2013-12-19 Impact factor: 7.853
Authors: Cosima Locher; Helen Koechlin; Sean R Zion; Christoph Werner; Daniel S Pine; Irving Kirsch; Ronald C Kessler; Joe Kossowsky Journal: JAMA Psychiatry Date: 2017-10-01 Impact factor: 21.596
Authors: Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker Journal: BMC Psychiatry Date: 2014-07-02 Impact factor: 3.630